MedTrace Logo

Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients

NCT02970747 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 359

Last updated 2025-11-25

No results posted yet for this study

Summary

The objective of this non-interventional study (NIS) is to evaluate patients' adherence and persistence to carfilzomib therapy in combination with lenalidomide and dexamethasone or in combination with dexamethasone alone or in combination with daratumumab and dexamethasone in adult patients with multiple myeloma (MM) who have received at least one prior therapy in a real-life setting.

Conditions

  • Multiple Myeloma in Relapse

Interventions

DRUG

Carfilzomib

In accordance with SmPC.

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • iOMEDICO AG

    lead INDUSTRY

Principal Investigators

  • Wolfgang Knauf, Professor · Centrum für Hämatologie und Onkologie Bethanien, Germany, 60389 Frankfurt a.M.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-25
Primary Completion
2025-04-26
Completion
2025-04-26

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02970747 on ClinicalTrials.gov